Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month ended January 31, 2023
Principal Executive Office: Level 3, 460 Bourke Street, Melbourne, VIC 3000, Australia
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a cover sheet incorporating exhibits by reference.
Exhibits Submitted:
- Exhibit 99.1: Appendix 4C and Quarterly Cash Flow Report
Investors must refer to the attached Exhibit 99.1 for detailed financial data.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. Such information is expected to be contained within the referenced Appendix 4C and Quarterly Cash Flow Report.
Guidance, Outlook, and Risks
The filing text does not include management commentary, guidance, outlook, or specific risk factors. The registrant is identified as a "development stage enterprise," which typically implies ongoing research and development activities without commercial revenue, though specific operational updates are not detailed in this cover document.
Important Facts for Investor Verification
- Verify the contents of Exhibit 99.1 (Appendix 4C and Quarterly Cash Flow Report) for actual financial figures, as they are not listed in the cover text.
- Confirm the company's status as a development stage enterprise and its implications for cash burn and funding needs.
- Note that this Form 6-K is incorporated by reference into multiple Registration Statements on Form S-8 and Form F-3.
- Check the signature date of January 31, 2023, signed by Geoffrey P. Kempler, Chairman.